EHA 2018 featured several eagerly awaited presentations on Hodgkin lymphoma. This included subgroup data of the ECHELON-1 trial in patients with high-risk features and data of a PET-based treatment de-escalation study. In non-Hodgkin lymphoma, the RELEVANCE study assessed the chemotherapy-free lenalidomide-rituximab combination as 1st line treatment for follicular lymphoma. In diffuse-large-B-cell lymphoma, updates were presented of the key studies evaluating CAR T-cell therapy and polatuzumab vedotin was found to improve the survival in relapsed/refractory patients.

(BELG J HEMATOL 2018;9(4):152–6)